Mitogen-activated protein kinase kinase 1 messenger RNA (MAP2K1 mRNA) (MAP2K1 mRNA)

MAP2K1 mRNA is the transcript of the Mitogen-activated protein kinase kinase 1 gene, which encodes the MEK1 protein, a key dual-specificity kinase in the MAPK/ERK signaling pathway [1]. This pathway is a critical regulator of fundamental cellular processes, including growth, proliferation, differentiation, and survival [2]. In many human cancers, the pathway is pathologically activated by mutations in upstream components like RAS or RAF, or by gain-of-function mutations within the MAP2K1 gene itself [3]. While the MEK1 protein is the direct target of several FDA-approved small-molecule inhibitors such as Trametinib and Cobimetinib, the MAP2K1 mRNA represents a strategic target for gene-silencing modalities [4]. Therapeutic approaches like antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are designed to bind specifically to the MAP2K1 mRNA, leading to its degradation or the inhibition of its translation [5]. By reducing the total cellular pool of MEK1 protein, these RNA-targeted strategies aim to suppress oncogenic signaling and may provide an alternative for patients who develop resistance to traditional kinase inhibitors [6].

Other names

MEK1 mRNAMKK1 mRNAMAPKK1 mRNAPRKMK1 mRNAERK activator kinase 1 mRNA

Antisense inhibition of translation and RNA interference-mediated mRNA degradation; small-molecule inhibition of the encoded MEK1 protein.